Autopsy report · NCT02406027
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 3 years before it stopped.
- 90 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Conditions
- Alzheimer Disease
- Interventions
- JNJ-54861911, 10 mg; JNJ-54861911, 25 mg; Placebo; JNJ-54861911, 5 mg
- Participants
- 90
- Sites
- 17
- Countries
- Belgium, France, Germany, Netherlands, Spain, Sweden
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.